The defined daily dose, a popular measurement of antimicrobial use, may underestimate the use of antimicrobials that are dose-adjusted in patients with renal insufficiency. To evaluate the effect of renal dysfunction on these measures, we performed a retrospective cohort study that involved patients receiving ceftriaxone, levofloxacin, or vancomycin, with use of defined daily doses and 2 methods based on therapy duration-stopstart days (i.e., entire therapy duration) and transaction days (i.e., unique therapeutic days). The vancomycin use rate for patients with renal insufficiency was 36% lower than that of patients with normal renal function for defined daily doses, and it was 23% lower for transaction days; for levofloxacin, there was a 27% rate reduction for the defined daily dose. No significant reduction was noted when the stop-start day method was used. Compared with the defined daily dose method, measures of therapy duration are less affected by renal function and may improve comparisons between populations.
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Antimicrobial resistance among pathogens that cause hospital-acquired infection has increased dramatically, resulting in both increased health care costs and increased patient morbidity and mortality [1] . Because antimicrobial use is a major driver of antimicrobial resistance [2] , several initiatives have been implemented to improve prescribing practices [3] . Measurement of antimicrobial use is necessary to help determine the effectiveness of such initiatives. Interinstitutional comparisons of aggregated antimicrobial use have been performed by the National Nosocomial Infections Surveillance (NNIS) system. The NNIS Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Pro-ject published pooled antimicrobial use rates for intensive care units (ICUs) and non-ICU areas in sentinel hospitals as a benchmark for other institutions [4] . Because health care facilities often have heterogeneous patient populations, the methods used to compare antimicrobial use rates between institutions must allow for meaningful comparisons of different patient populations.
In the United States, antimicrobial use surveillance frequently is performed with use of the defined daily dose method, which is derived by dividing the aggregate use of a specific antimicrobial by a defined standard daily dose for that drug. The defined daily dose is a popular measure because it is easily applied to readily available aggregate pharmacy purchasing and dispensing data. However, the defined daily dose may not accurately reflect the use of certain antimicrobial agents in populations that require dose adjustment on the basis of weight or renal function, such as pediatric patients or patients with renal insufficiency. Variations in the prevalence of these patient types between institutions may complicate interinstitutional comparisons [5] [6] [7] [8] .
In addition, because hospitals may use one of several methods to quantify gram consumption, and because the defined daily dose may not reflect local dosing patterns [9] , comparisons of defined daily doses are further constrained.
Despite being used commonly, the defined daily dose method for comparison of antimicrobial use rates across different populations has not been well studied. To investigate the effect of renal insufficiency on antimicrobial use measurements, we conducted a retrospective cohort study of patients who received vancomycin, levofloxacin, or ceftriaxone. We compared the rates of defined daily dose use with 2 alternative antimicrobial use measurements that are based on duration of therapy, and we evaluated the effect of renal insufficiency on each measure. To determine whether an effect of renal dysfunction on antimicrobial use measurements would affect interinstitutional comparisons of antimicrobial use rates, we also compared the prevalence of renal insufficiency in patients receiving care in 2 separate acute care facilities and 1 long-term care facility.
PATIENTS AND METHODS

Patients and setting.
We evaluated all parenteral courses of vancomycin, levofloxacin, or ceftriaxone therapy administered to adult inpatients of Cook County Hospital (acute care hospital A), a 550-bed public teaching hospital in Chicago, during an 18-month period from 1 April 2000 through 30 September 2001. Because use is routinely reported according to class of antimicrobial agent, the cohort was divided 3 ways according to the drug groups. We included therapy courses for patients who received у1 of the study antimicrobials.
We selected vancomycin, levofloxacin, and ceftriaxone for study because each is a commonly used representative of an important antimicrobial class (glycopeptides, fluoroquinolones, and cephalosporins, respectively) and because each has different dose adjustment requirements for patients with renal insufficiency. For parenteral vancomycin therapy, the manufacturer recommends adjustment (decreasing) of the dose frequency without gram dose adjustment for most adult patients; for levofloxacin, the gram dose is decreased initially, and then the frequency of administration is decreased; and for ceftriaxone, no adjustments in dose or frequency are required [10] . Dose adjustment associated with renal insufficiency is not always class-specific-for example, unlike ceftriaxone, most cephalosporins are cleared primarily via the kidney and require dose adjustment for patients with renal insufficiency.
We obtained the following data from the Chicago Antimicrobial Resistance Project [3] data warehouse: age, serum creatinine concentration, weight, height, length of hospital stay, sex, and race. For patients with multiple serum creatinine concentration determinations, values obtained 1 week before the commencement of antimicrobial therapy until the final day of therapy were aggregated and analyzed as the mean serum creatinine concentration. Weight and height values that were missing for these patients (data were missing for 51% and 48% of patients, respectively) were imputed using decision tree imputation [11, 12] on the basis of data (antimicrobial received, age, mean serum creatinine concentration, gram dose, therapy duration, length of hospital stay, ward location, sex, and race) from the entire cohort. Body mass index was calculated from the ratio of weight over height squared. For our analysis, patients were assigned to a hospital ward on the basis of where the patient spent the majority of the hospital stay.
Antimicrobial use method. Three antimicrobial use methods-defined daily doses, start-stop days, and transaction days-were calculated for each patient's hospital stay. Although it is possible for patients to receive the same antimicrobial therapy more than once during the same hospital stay, we assumed that only 1 course of therapy with each study antimicrobial was given per hospital stay.
"Defined daily doses" were defined as the ratio of total grams dispensed from the pharmacy over the most common adult daily dose [13] ; for this analysis, the most common daily doses were vancomycin, 2000 mg, levofloxacin, 500 mg, and ceftriaxone, 1000 mg. Because the defined daily dose is the ratio of 2-g measures, it has "defined daily doses" as the unit of measure. The defined daily dose measure is directly influenced by gram dose adjustments and can be indirectly influenced by adjustments in dosing frequency.
"Transaction days" were defined as the total number of distinct days the antimicrobial was dispensed to the individual patient from the pharmacy. This measure is not affected by gram dose adjustments and was designed to assess the direct affects of dosing frequency on antimicrobial use. "Stop-start days" were defined as the difference (in days) between the last day and the first day the drug was dispensed from the pharmacy plus 1 day. Therefore, the stop-start day method was not affected by gram dose and was less affected by the frequency of dosing compared with the defined daily dose and transaction day methods. However, stop-start days have the potential to overestimate antimicrobial use when there are multiple therapeutic courses of the same antimicrobial therapy during a patient's hospital stay.
Statistical analysis. In a bivariate analysis, patient-level covariates were transformed to maximize the linear fit to each antimicrobial use measurement. Antimicrobial use rates for each patient were calculated from the ratio of the defined daily doses, stop-start days, and transaction days over the length of hospital stay for each patient, and the rates are expressed per 100 patient-days. Antimicrobial use rates were compared according to different patient characteristics; statistical differences were tested with use of Student's t test for categorical variables, and Pearson's correlation was used to find significant correlations for continuous variables. Multivariable linear-regression models were constructed for each antimicrobial use measurement for each antimicrobial group with use of the antimicrobial use rate as the dependent variable and log-transformed mean serum creatinine concentration as the main independent variable. Age, weight, body mass index, and sex were selected as candidate covariates because of their potential effects on dosing. Effect modification was investigated by entering multiplicative interaction variables into the models. Final models were selected by forward selection, and variables were entered at a confidence level of . a p .05 For further evaluation of the threshold effect of renal function on the rate of antimicrobial use, we categorized the patient's mean serum creatinine concentration into quartiles and graphically analyzed pooled use rates across these categories by antimicrobial group. Following this graphical analysis, we constructed additional multivariable models where elevated serum creatinine concentration (i.e., upper quartile/renal insufficiency) was the main independent variable. The rates of antimicrobial use for patients who had renal insufficiency were then compared with rates for patients who had normal renal function.
We examined the variability of renal function between different patient populations with use of a cross-sectional sample of all patients who had у1 serum creatinine concentration result reported from 1 of 3 institutions within the Cook County Bureau of Health Services from 1 September through 30 November 2001. In addition to Cook County Hospital (acute care hospital A), we included a 120-bed community hospital (acute care hospital B) and a 669-bed acute and long-term care facility (LTCF). Repeated serum creatinine concentration determinations were collected for the entire length of hospital stay, and the mean serum creatinine concentration was determined. Statistical differences of patient-level log-transformed mean serum creatinine concentrations were tested with analysis of variance, and Bonferroni t tests of differences between mean values were used for multiple hospitalwide, non-ICU, and ICU pairwise comparisons between institutions and within ICU type strata only at the acute care hospital A and acute care hospital B facilities. The mean serum creatinine concentrations were ranked and categorized into quartiles, and patients whose mean concentration ranked in the upper quartile were considered to have renal insufficiency. Differences in the prevalence of renal insufficiency were tested with the x 2 test of independence. All statistical analyses were performed with SAS, version 8.2 (SAS Institute). 
RESULTS
During the study period there were 38,666 adult inpatient admissions, during which 3711 patients (10%) received у1 of the study antimicrobials, accounting for 4422 therapeutic courses of ceftriaxone (52%), levofloxacin (26%), or vancomycin (22%). Of the 3711 patients, 183 (5%) received all 3 antimicrobials, and 1178 (32%) received 2 of the study antimicrobials. Significant differences among the 3 antimicrobial groups were observed for length of hospital stay (patient-days), mean serum creatinine concentration, weight, prevalence of renal insufficiency, race, and antimicrobial use measurements (table 1) .
Among patients who received vancomycin therapy, the mean serum creatinine concentration was significantly ( ) in-P ! .01 versely correlated with defined daily doses ( ), transr p Ϫ.30 action days ( ), and stop-start days ( ); age r p Ϫ.25 r p Ϫ.11
was also significantly inversely correlated with defined daily doses ( ), transaction days ( ), and stop-start r p Ϫ.19 r p Ϫ.19 days ( ). Among patients who received levofloxacin r p Ϫ.15 therapy, the mean serum creatinine concentration was significantly ( ) inversely correlated with defined daily doses P ! .01 ( ) and transaction days ( ), and all rates for r p Ϫ.21 r p Ϫ.08 female patients were significantly ( ) greater than the rates P ! .01 for male patients (80.3 vs. 73.5 defined daily doses per 100 patient-days, 61.6 vs. 57.7 stop-start days per 100 patient-days, and 58.5 vs. 53.7 transaction days per 100 patient-days, respectively). Among the patients who received ceftriaxone therapy, no significant correlates were found for any antimicrobial use measurement. Race and body mass index failed to explain any of the variation in any of antimicrobial use measurements.
After categorization of mean serum creatinine concentration by quartiles, the rate of antimicrobial use among patients with renal insufficiency (i.e., patients in the upper quartile) was found to be lower than was the rate for other patients, as defined by defined daily doses and transaction days in the levofloxacin and vancomycin groups (figure 1). However, no such effect was noted with use of the stop-start day method. On multivariable analysis, the rate of vancomycin use among patients who had renal insufficiency compared with patients who had normal renal function was 36% (table 2) lower with use of defined daily doses ( ) and 23% lower (table 2) P ! .01 with use of transaction days ( ). The rate of levofloxacin P ! .01 use among patients who had renal insufficiency compared with patients who had normal renal function was 27% lower (table 2) with use of defined daily doses ( ). The stop-start day P ! .01 method was not significantly affected by renal insufficiency in any antimicrobial group when adjusted for other factors (table  2) . Other independent predictors of antimicrobial use included age in the vancomycin group for all 3 antimicrobial use measurements. Receipt of у1 of the study antimicrobials did not influence any antimicrobial use measurement.
For our comparison of the mean serum creatinine concentration and prevalence of ICU-specific renal insufficiency in the 3 institutions, we evaluated data for 10,238 patients (71% from acute care hospital A, which has 5 adult ICUs; 17% from acute care hospital B, which has 2 adult ICUs; and 11% from the LTCF, which has only 1 general ICU ward). When all ward locations, non-ICU, and ICU strata were compared, the overall mean serum creatinine concentrations and prevalences of renal insufficiency differed significantly among the 3 institutions (table 3). When ICU wards were compared within acute care hospital A, overall differences were significant for mean serum creatinine concentration and prevalence of renal insufficiency (table 3) .
DISCUSSION
We found that the rate of antimicrobial use is significantly decreased among patients who had renal insufficiency compared with those who had normal renal function when use is measured by the defined daily dose method for both vancomycin (decrease of 36%) and levofloxacin (decrease of 27%). The 2 antimicrobial use measurements that use therapy duration (i.e., transaction days and stop-start days) were less affected by variations in renal function.
Our findings are consistent with the clinical practice of prescribing antimicrobials; adjustments in the frequency of administration and gram dose adjustments are common for patients with renal insufficiency, and the type and magnitude of adjustment are antimicrobial specific. Thus, for patients with renal insufficiency, we expect the defined daily dose method to underestimate use for medications with regimens that are typically adjusted by either gram dose or frequency of adminis- tration, and we expect the transaction day method to be affected only by adjustment in the frequency of administration. For therapies that require only gram dose adjustment, we expect the defined daily dose method, but not the transaction day and stop-start day methods, to underestimate use. In practice, for patients who receive vancomycin, the frequency of administration is adjusted before dose adjustments are made, whereas, for patients who receive levofloxacin, the gram dose is adjusted before the dosing frequency is adjusted. There is typically no adjustment required for patients who receive ceftriaxone and who have renal insufficiency. We also found that the prevalence of renal insufficiency varied significantly between institutions and between patient care units within an institution. This suggests that interunit and interinstitutional antimicrobial use comparisons for some antimicrobials using the defined daily dose method will likely be confounded by differences in renal function among patients in different health care facilities. Stratification of use rates according to patient population (i.e., ICU type) can help control for the effect of renal insufficiency when making defined daily dose comparisons between institutions, as was done in project ICARE [5] .
In our evaluation of other independent predictors of antimicrobial use, it was surprising to find that body mass index had no influence on any measure for the antimicrobials studied. However, weight and height data were imputed for 51% and 49% of the therapy courses, respectively. Although data for therapy courses with missing height and weight values were not distinguishable from courses with these measurements (data not shown), we cannot conclude that these missing data are a result of random omission. Nevertheless, it appears that, in practice, gram dose adjustments are not frequently made on the basis of patient weight.
We used patients' serum creatinine concentration as an indicator of renal function. A more precise measure of renal function-for example, a timed urine creatinine collectionrarely is performed. Use of a formula to calculate creatinine clearance [14] would have been a more accurate measure of renal function; however, by use of such a measure, we would have been unable to assess the independent effects of age, sex, and weight on antimicrobial use. In addition, our findings suggest that, after controlling for serum creatinine level, sex and weight do not explain the variation of antimicrobial use: age affected vancomycin use but not levofloxacin or ceftriaxone use. Therefore, because the variables used to calculate creatinine clearance were evaluated in the multivariable models, it is likely that our results would be similar had we used estimated creatinine clearance.
Although our definition of renal insufficiency could be considered arbitrary, others have defined renal insufficiency on the basis of an elevated serum creatinine concentration of 1.4 mg/ dL [15] , which is similar to our upper quartile cutoff point of 1.31 mg/dL. Although not all clinicians will adjust the dose or frequency of administration if the patient has a serum creatinine concentration near 1.31 mg/dL, in our sample, we noted significant gram dose adjustments for vancomycin and levofloxacin therapies and frequency adjustments for vancomycin therapy for patients who had serum creatinine concentrations of 11.31 mg/dL. In addition, the vancomycin and levofloxacin defined daily dose should proportionally decrease with increasing serum creatinine concentrations. Therefore, with use of our upper quartile cutoff point, the differences in defined daily dose rates between patients with renal insufficiency and those with normal function should be considered conservative; in other words, elevated serum creatinine concentration cutoff points (11.31 mg/dL) would result in greater defined daily dose differences for both vancomycin and levofloxacin.
Antimicrobial use estimates based on therapy duration have several limitations. The need for obtaining patient-level (i.e., nonaggregated) information may be the most important. Although the transaction day method is directly affected by dosing frequency among drug regimens that are administered less frequently than once per day, this limitation also applies to the defined daily dose method. Because the dosing frequencies of many antimicrobials are not adjusted, this limitation should not be generalized to all antimicrobials for which renal dose adjustment is required (e.g., ampicillin) [13] . Because the stopstart days method uses first and last dates of receipt, overestimation of antimicrobial use may occur among patients who have extended hospital stays, who are more likely to receive the same therapy twice during their stay, unless the temporal gap between courses is recognized and omitted. This did not appear to affect our results for patients in an acute care hospital, but, unless corrected, it may bias the measurement of antimicrobial use for patients with longer stays at a health care facility (e.g., residents of LTCFs). However, detection of and adjustment for interruptions in therapy should be feasible when one uses information systems that are capable of collecting patient-level data.
In conclusion, institutions that use defined daily dose-based measurements to compare interhospital or interunit antimicrobial use must be aware of the limitations of these measurements. Two antimicrobial use methods that quantify duration of antimicrobial therapy-the transaction day method and the stop-start day method-better estimated hospitalwide rates of levofloxacin and vancomycin use among patients with renal insufficiency. The accuracy provided by the use of the transaction day and stop-start day methods warrant consideration of these 2 methods to measure antimicrobial use.
